Murhekar Kanchan M, Anuratha Jayaram N, Majhi Urmila, Rajkumar Thangarajan
Departments of Pathology, Cancer Institute (WIA), Adyar, Chennai, India.
Indian J Med Paediatr Oncol. 2009 Jul;30(3):99-102. doi: 10.4103/0971-5851.64254.
Beta Human Chorionic Gonadotropin (βHCG), a marker of the trophoblastic neoplasm, is also secreted by non-trophoblastic neoplasms including gastric carcinomas. Its role in disease progression remains unclear.
To investigate the incidence of βHCG positivity in gastric carcinomas and correlate its presence with the biological behavior of the tumor.
A hospital-based, immunohistochemical study.
One hundred and fifty formalin-fixed, paraffin-embedded tissue specimens from histopathologically confirmed cases of gastric carcinoma were immunostained using an indigenously developed antibody against βHCG. Tumors with diffuse reactivity to βHCG were considered as positive. Those with occasional, focal or no reactivity to βHCG were considered as negative.
Differences in βHCG staining were compared according to the histological grade and surgical stage using the χ(2) test. Using the Cox proportional hazards model, the time till the onset of development of an adverse outcome after surgery (defined as death, local or distant metastasis) was compared between the bHCG positive and negative tumors.
Twenty-eight (18.7%) of the 150 specimens were βHCG positive. No association was found between the histological grade (P=0.49) and the surgical stage (P=0.19) with βHCG positivity. The median disease-free survival after surgery was not different among βHCG positive and negative tumors. Risk of an adverse outcome after surgery was significantly associated with the stage of the tumor (Hazard ratio=2.9, 95% confidence interval: 1.1-7.4). No association was observed with grade or βHCG positivity.
βHCG immunoreactivity was observed in about one-fifth of the gastric cancers. βHCG reactivity, however, played no role in the biological behavior.
β人绒毛膜促性腺激素（βHCG）是滋养层肿瘤的标志物，也由包括胃癌在内的非滋养层肿瘤分泌。其在疾病进展中的作用仍不清楚。
研究胃癌中βHCG阳性的发生率，并将其存在与肿瘤的生物学行为相关联。
一项基于医院的免疫组织化学研究。
对150例经组织病理学确诊的胃癌福尔马林固定、石蜡包埋组织标本，使用自行研制的抗βHCG抗体进行免疫染色。对βHCG呈弥漫性反应的肿瘤视为阳性。对βHCG呈偶尔、局灶性或无反应的肿瘤视为阴性。
使用χ²检验，根据组织学分级和手术分期比较βHCG染色的差异。使用Cox比例风险模型，比较βHCG阳性和阴性肿瘤术后出现不良结局（定义为死亡、局部或远处转移）的发生时间。
150例标本中有28例（18.7%）βHCG呈阳性。未发现组织学分级（P = 0.49）和手术分期（P = 0.19）与βHCG阳性之间存在关联。βHCG阳性和阴性肿瘤术后的无病生存期中位数无差异。术后不良结局的风险与肿瘤分期显著相关（风险比 = 2.9，95%置信区间：1.1 - 7.4）。未观察到与分级或βHCG阳性存在关联。
约五分之一的胃癌中观察到βHCG免疫反应性。然而，βHCG反应性在生物学行为中不起作用。
